Trifecta-Kidney cfDNA-MMDx Study (NCT04239703)

🧪 Interventions in This Study

• MMDx (DIAGNOSTIC_TEST)
• Prospera (DIAGNOSTIC_TEST)
• HLA antibody (DIAGNOSTIC_TEST)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• Tampa General Hospital — Tampa, Florida
• University of Maryland School of Medicine — Baltimore, Maryland
• The Johns Hopkins University, School of Medicine — Baltimore, Maryland
• Detroit Medical Center, Harper University Hospital of Wayne State University — Detroit, Michigan
• Henry Ford Hospital — Detroit, Michigan
• Barnes-Jewish Hospital, Washington University at St. Louis — St Louis, Missouri
• University Hospitals Cleveland Medical Ctr. — Cleveland, Ohio
• Cleveland Clinic — Cleveland, Ohio
• Intermountain Transplant Services — Murray, Utah
• Virginia Commonwealth University Medical Center — Richmond, Virginia
• Division of Nephrology & UW Organ Transplant Center University of Washington — Seattle, Washington
• Department of Nephrology, The Royal Melbourne Hospital 1 South East — Melbourne,
• University of Alberta, Department of Medicine — Edmonton, Alberta
• ST. Paul's Hospital, 6A Providence Building, 1081 Burrard Street — Vancouver, British Columbia
• University Hospital Merkur Renal Division — Zagreb,
• Institute for Clinical and Experimental Medicine (IKEM) — Prague,
• Charite-Medical University of Berlin Department of Nephrology — Berlin,
• Centre of Nephrology, Vilnius University Hospital Santaros Klinikos — Vilnius,
• Department of Nephrology and Transplantation Medical University in Bialystok — Bialystok,
• University Hospital nr1 Bydgoszcz, Klinika Transplantologii — Bydgoszcz,
• Medical University of Gdańsk Klinika Nefrologii Transplantologii i Chorób Wewnętrznych — Gdansk,
• Medical University of Silesia — Katowice,
• Department of Transplantation and General Surgery, Wojewodzki Hospital — Poznan,
• Department of Nephrology, Transplantation and Internal Medicine, University Hospital n.2 — Szczecin,
• Pomeranian Medical University, Samodzielny Publiczny Woj. Szpital Zespolony, Oddzial Nefrologii i Transplantacji Nerek — Szczecin,

📞 Contact the Study Coordinator

Phone: (780) 492-1725

Email: konrad@ualberta.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Kidney Transplant Rejection

• Microbiome and Immunosuppression: The Mission Study — Minneapolis, Minnesota
• Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection — Chicago, Illinois
• The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) — Birmingham, Alabama
• PROACT Pilot Trial — Vancouver, British Columbia
• AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function — Gainesville, Florida

Explore by condition: All Kidney Transplant Rejection clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.